KRYS
Krystal Biotech, Inc.
KRYS's fundamentals are strong: revenue grew 26% and its operating margin rose 6 points to 48%. At 42x earnings, it's trading in line with its usual 44x. Analysts expect that strong growth to continue.
KRYS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
KRYS's revenue, profitability, cash flow and balance sheet are all currently healthy.
KRYS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $261 | -15% |
| Forward | 35x | $306 | — |
| Current | 42x | $306 | — |
| Fair | 44x | $321 | +5.1% |
| Expensive | 79x | $579 | +89% |
Historical ranges are pointers, not guarantees.
KRYS's PE is in its fair range at 42x. If earnings grow as analysts expect, today's price would be 35x next year's earnings, in its cheap range.
KRYS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for KRYS, with profitability improving.
KRYS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.68 | +18% |
| Q3 2026 | $7.36 | +10% |
| Q2 2026 | $7.97 | +62% |
| Q1 2026 | $7.47 | +79% |
| Q4 2025 | $6.84 | +128% |
| Q3 2025 | $6.68 | +221% |
| Q2 2025 | $4.93 | +24% |
| Q1 2025 | $4.17 | +91% |
| Q4 2024 | $3.00 | +669% |
KRYS's earnings per share have climbed steadily: $7.36 over the past year, up 10% from the year before, and higher year over year for 13 quarters in a row.
KRYS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.3M | +30% |
| Q2 2026 | $119.2M | +24% |
| Q1 2026 | $116.4M | +32% |
| Q4 2025 | $107.1M | +18% |
| Q3 2025 | $97.8M | +17% |
| Q2 2025 | $96M | +37% |
| Q1 2025 | $88.2M | +95% |
| Q4 2024 | $91.1M | +116% |
KRYS's revenue has grown year over year every quarter since late 2024: $127M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 56% | +14 points |
| Q2 2026 | 49% | +8.1 points |
| Q1 2026 | 46% | +5.1 points |
| Q4 2025 | 41% | -4.1 points |
| Q3 2025 | 42% | +16 points |
| Q2 2025 | 41% | +29 points |
| Q1 2025 | 41% | +56 points |
| Q4 2024 | 45% | +38 points |
KRYS's operating margin was 56% last quarter, up 14 points from the same quarter a year ago, near the top of its range since 2023.
KRYS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $90.3M | +138% |
| Q2 2026 | $71.2M | +40% |
| Q1 2026 | $73.2M | +196% |
| Q4 2025 | $75.4M | +45% |
| Q3 2025 | $38M | -34% |
| Q2 2025 | $50.8M | +$56.1M |
| Q1 2025 | $24.8M | +69% |
| Q4 2024 | $52M | +$61.1M |
KRYS has burned cash in most quarters: $310M over the past year, up 87% from the year before.
KRYS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +181K shares |
| 1 year | +3.4% | +1M shares |
| 3 years | +6.7% | +1.9M shares |
| 5 years | +39% | +8.6M shares |
| Available history | +94% | +14.9M shares |
KRYS has 31M diluted shares, up 3.4% from a year ago.
KRYS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.5x | Net Cash |
| Q1 2025 | -2.7x | Net Cash |
| Q4 2024 | -4.8x | Net Cash |
KRYS has more cash than debt.
KRYS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.9 | Neutral |
| Stochastic | 31.3 | Neutral |
KRYS's weekly RSI is 46 (neutral) and its Stochastic is 31 (neutral).
KRYS PE vs Healthcare Sector
| Metric | KRYS | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 61% above |
| PE % | 42 | 29 | 13 pts above |
KRYS is trading at 42x earnings, a 61% premium to the Healthcare sector's median of 26x.
KRYS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $320.8 | 4.7% below |
| 20 week MA | $336.9 | 9.3% below |
| 50 week MA | $300.8 | 1.6% above |
| 100 week MA | $231.7 | 32% above |
| 200 week MA | $184.5 | 66% above |
KRYS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 66% above its 200-week average.
KRYS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $60.6 | +0.7% |
| 2021 | $60.6 | $72.3 | +19% |
| 2022 | $72.3 | $76.6 | +5.9% |
| 2023 | $76.6 | $124.1 | +62% |
| 2024 | $124.1 | $159.3 | +28% |
| 2025 | $159.3 | $252.2 | +58% |
| 2026 YTD | $252.2 | $305.7 | +21% |
KRYS has finished every year since 2020 higher, and it's up 21% so far in 2026.